Biotech Values

[genisi]

VRTX said they will initiate combo study of telaprevir and a ViroChem's polymerase inhibitor later this year.

Nucs have a high genetic barrier to resistance and can exhibit antiviral activity as strong as protease inhibitors, so it's a good combo. But we might see other combos like with Cyclophilin inhibitor, that may be less prone to resistance and could be a candidate used together with direct antivirals trying to replace IFN in the future HCV cocktail.